Detalles de la búsqueda
1.
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
N Engl J Med
; 383(24): 2333-2344, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33085857
2.
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
J Gen Intern Med
; 37(8): 1917-1924, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34100235
3.
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia.
J Thromb Thrombolysis
; 53(3): 708-711, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34694540
4.
COVID-19 and rheumatoid arthritis.
Curr Opin Rheumatol
; 33(3): 255-261, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33625043
5.
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic.
Ann Rheum Dis
; 80(5): 660-666, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33257496
6.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Ann Rheum Dis
; 80(9): 1137-1146, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34049860
7.
Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study.
Rheumatology (Oxford)
; 60(6): 2653-2660, 2021 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33175975
8.
COVID-19 and Disease-Modifying Anti-rheumatic Drugs.
Curr Rheumatol Rep
; 23(5): 28, 2021 04 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33893890
9.
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.
Ann Rheum Dis
; 79(9): 1156-1162, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32457048
10.
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C et al.
Ann Rheum Dis
; 82(6): e131, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33692020
11.
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al.
Ann Rheum Dis
; 81(7): e132, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32586919
12.
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al.
Ann Rheum Dis
; 81(8): e135, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32660976
13.
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.
Ann Rheum Dis
; 81(2): 289-291, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34489304
14.
Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al.
Ann Rheum Dis
; 80(5): e64, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32546600
15.
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
Ann Rheum Dis
; 80(6): 817-819, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33436385
16.
Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning-Derived Chest Radiograph Scores.
Arthritis Care Res (Hoboken)
; 75(3): 657-666, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313091
17.
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance.
Arthritis Care Res (Hoboken)
; 75(1): 53-60, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239292
18.
Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study.
Arthritis Care Res (Hoboken)
; 74(5): 741-747, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874123
19.
Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study.
ACR Open Rheumatol
; 4(3): 238-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34890478
20.
DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study.
medRxiv
; 2022 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35169813